Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) (002603)

1. Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) become a leader in the industry with innovative collateral disease theory

The core competitive advantage of the company is the innovation of collateral disease theory, Self built "collateral disease syndrome treatment theory system". Collateral disease theory provides strong theoretical support for the company's research on intractable diseases such as cardiovascular and cerebrovascular diseases and tumors, guides the company's drug research and development in cardiovascular and cerebrovascular diseases and cold and respiratory diseases, and then confirms the curative effect through evidence-based medicine, so as to win a high market share and help the company become a leader in the industry.

2. As a representative of scientific and technological innovation of traditional Chinese medicine, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) has realized the whole industry chain through acquisition, merger and establishment of new companies with the general trend in recent years

The company is mainly engaged in patented traditional Chinese medicine. In recent years, it has enriched various business lines through mergers and acquisitions and the establishment of new companies, so as to realize the whole industrial chain. It has initially formed a new pattern from raw material breeding, pharmaceutical R & D and production, pharmaceutical logistics, e-commerce operation and export.

In recent years, it has become an industry trend for pharmaceutical enterprises to build and expand their own business platforms in order to realize the whole industry chain. The realization of the whole industry chain will help to realize business integration, maximize resource utilization, reduce the time and money cost of each link, and help the enterprise grow.